“Standard Care Vs Corticosteroid For Retinal Vein Occlusion (Score) Study System For Evaluation Of Stereoscopic Color Fundus Photographs And Fluorescein Angiograms: Score Study Report 9.”. Arch Ophthalmol 128 (9). Arch Ophthalmol: 1140-5. doi:10.1001/archophthalmol.2010.193.
. 2010. “The Standard Care Vs Corticosteroid For Retinal Vein Occlusion (Score) Study System For Evaluation Of Optical Coherence Tomograms: Score Study Report 4.”. Arch Ophthalmol 127 (11). Arch Ophthalmol: 1461-7. doi:10.1001/archophthalmol.2009.277.
. 2009. “Score2 Report 5: Vision-Related Function In Patients With Macular Edema Secondary To Central Retinal Or Hemiretinal Vein Occlusion.”. Am J Ophthalmol 184. Am J Ophthalmol: 147-156. doi:10.1016/j.ajo.2017.10.008.
. 2017. “Score2 Report 13: Intraretinal Hemorrhage Changes In Eyes With Central Or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab Or Observation. Secondary Analysis Of The Score And Score2 Clinical Trials.”. Am J Ophthalmol 222. Am J Ophthalmol: 185-193. doi:10.1016/j.ajo.2020.08.030. https://pubmed.ncbi.nlm.nih.gov/32828880/#affiliation-4.
. 2020. “Score Study Report 8: Closed Tests For All Pair-Wise Comparisons Of Means.”. Drug Inf J 44 (4). Drug Inf J: 405-420. doi:10.1177/009286151004400405.
. 2010. “Score Study Report 7: Incidence Of Intravitreal Silicone Oil Droplets Associated With Staked-On Vs Luer Cone Syringe Design.”. Am J Ophthalmol 148 (5). Am J Ophthalmol: 725-732.e7. doi:10.1016/j.ajo.2009.06.004.
. 2009. “Score Study Report 3: Study Design And Baseline Characteristics.”. Ophthalmology 116 (9). Ophthalmology: 1770-1777.e1. doi:10.1016/j.ophtha.2009.03.022.
. 2009. “Score Study Report 2: Interobserver Agreement Between Investigator And Reading Center Classification Of Retinal Vein Occlusion Type.”. Ophthalmology 116 (4). Ophthalmology: 756-61. doi:10.1016/j.ophtha.2008.11.015.
. 2009. “Score Study Report 12: Development Of Venous Collaterals In The Score Study.”. Retina 33 (2). Retina: 287-95. doi:10.1097/IAE.0b013e318263d106.
. 2013. “Score Study Report #11: Incidences Of Neovascular Events In Eyes With Retinal Vein Occlusion.”. Ophthalmology 118 (7). Ophthalmology: 1364-72. doi:10.1016/j.ophtha.2010.11.020.
. 2011. “Score Study Report 1: Baseline Associations Between Central Retinal Thickness And Visual Acuity In Patients With Retinal Vein Occlusion.”. Ophthalmology 116 (3). Ophthalmology: 504-12. doi:10.1016/j.ophtha.2008.10.017.
. 2009. “A Randomized Trial Comparing The Efficacy And Safety Of Intravitreal Triamcinolone With Observation To Treat Vision Loss Associated With Macular Edema Secondary To Central Retinal Vein Occlusion: The Standard Care Vs Corticosteroid For Retinal Vein Occlus”. Arch Ophthalmol 127 (9). Arch Ophthalmol: 1101-14. doi:10.1001/archophthalmol.2009.234.
. 2009. “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy For Macular Edema Due To Central Retinal Or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis Of A Randomized Clinical Trial.”. Jama Ophthalmol. Jama Ophthalmol. doi:10.1001/jamaophthalmol.2019.1519.
. 2019. “Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy For Macular Edema Due To Central Retinal Or Hemiretinal Vein Occlusion: Score2 Report 10: A Secondary Analysis Of The Score2 Randomized Clinical Trial.”. Jama Ophthalmol. Jama Ophthalmol. doi:10.1001/jamaophthalmol.2019.3947.
. 2019. “Month 12 Outcomes After Treatment Change At Month 6 Among Poor Responders To Aflibercept Or Bevacizumab In Eyes With Macular Edema Secondary To Central Or Hemiretinal Vein Occlusion: A Secondary Analysis Of The Score2 Study.”. Jama Ophthalmol 137 (3). Jama Ophthalmol: 281-287. doi:10.1001/jamaophthalmol.2018.6111.
. 2019. “Long-Term Physical Stability, Sterility, And Anti-Vegf Bioactivity Of Repackaged Bevacizumab In 2-Ml Glass Vials.”. Retina 39 (9). Retina: 1802-1809. doi:10.1097/IAE.0000000000002212.
. 2019. “Incidence, Risk Factors, And Timing Of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection For Macular Edema Secondary To Retinal Vein Occlusion: Score Study Report 15.”. Jama Ophthalmol 133 (9). Jama Ophthalmol: 1022-9. doi:10.1001/jamaophthalmol.2015.1823.
. 2015. “Effect Of Bevacizumab Vs Aflibercept On Visual Acuity Among Patients With Macular Edema Due To Central Retinal Vein Occlusion: The Score2 Randomized Clinical Trial.”. Jama 317 (20). Jama: 2072-2087. doi:10.1001/jama.2017.4568.
. 2017. “Comparison Of Monthly Vs Treat-And-Extend Regimens For Individuals With Macular Edema Who Respond Well To Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From The Score2 Randomized Clinical Trial.”. Jama Ophthalmol 136 (4). Jama Ophthalmol: 337-345. doi:10.1001/jamaophthalmol.2017.6843.
. 2018. “Baseline Predictors Of Visual Acuity And Retinal Thickness Outcomes In Patients With Retinal Vein Occlusion: Standard Care Versus Corticosteroid For Retinal Vein Occlusion Study Report 10.”. Ophthalmology 118 (2). Ophthalmology: 345-52. doi:10.1016/j.ophtha.2010.06.034.
. 2011. “Baseline Factors Associated With 6-Month Visual Acuity And Retinal Thickness Outcomes In Patients With Macular Edema Secondary To Central Retinal Vein Occlusion Or Hemiretinal Vein Occlusion: Score2 Study Report 4.”. Jama Ophthalmol 135 (6). Jama Ophthalmol: 639-649. doi:10.1001/jamaophthalmol.2017.1141.
. 2017.